TRVI
NASDAQ HealthcareTrevi Therapeutics, Inc. - Common Stock
Biotechnology
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
�� 市场数据
| 价格 | $15.23 |
|---|---|
| 成交量 | 7,151,652 |
| 市值 | 1.96B |
| 贝塔系数 | 1.000 |
| RSI（14日） | 87.8 超买 |
| 200日均线 | $10.29 |
| 50日均线 | $11.83 |
| 52周最高 | $15.76 |
| 52周最低 | $5.38 |
| Forward P/E | -26.96 |
| Price / Book | 10.67 |
🎯 投资策略评分
TRVI 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (89/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 TRVI in your text
粘贴任何文章、记录或帖子 — 工具将提取 TRVI 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.